Susan C. Fagan, Pharm.D.

Professor, Associate Head and Assistant Dean

Clinical and Administrative Pharmacy, Augusta, GA

Office: , Rm CJ-1020   
Voice: 706-721-4915
: sfagan@gru.edu


Pharm.D. , State Univ. of New York, Buffalo

BSc Pharmacy, Dalhousie University, Halifax, Nova Scotia

Research Interests

Stroke Pharmacotherapy

Focuses on the identification and development of new therapeutic strategies for acute ischemic stroke. Currently, this includes vascular protection after acute stroke as an attempt to improve functional recovery. Using both experimental and clinical approaches, research aims to improve the way in which stroke patients are treated.

Of Note

Post-doctoral Experience
Fellowship in Neuropharmacology, Dent Neurologic Institute, Buffalo, New York
Honors and Awards
Fellow of the American College of Clinical Pharmacy and the American Heart Association Stroke Council
Board-certified pharmacotherapy specialist
Member, Prevention Advisory Board of the National Stroke Association
Member, Leadership Committee of the American Heart Association Stroke Council
Member, American Heart Association Brain 1 study section, as well as two NIH study sections

Selected Publications

Ergul A, Alhusban A, Fagan SC. Angiogenesis: A Harmonized Target for Recovery after Stroke (Invited). Stroke 2012; 43:2270-2274

Alhusban A, Kozak A, Ergul A, Fagan SC. AT1 receptor antagonism modulates the angiogenic response of brain endothelial cells to angiotensin II: BDNF a novel mediator. J Pharmacol Exp Ther 2013; 344(2):348-359

Fouda A, Kozak A, Alhusban A, Switzer JA, Fagan SC. Antiinflammatory IL-10 is upregulated in both hemispheres after experimental ischemic stroke: Hypertension blunts the response. Exp Translational Stroke Med 2013, 5:12 DOI:10.1186/2040-7378-5-12. Nov 13

Ergul A, Abdelsaid M, Fouda A, Fagan SC. Cerebral neovascularization in diabetes: Implications for stroke recovery and beyond. Invited Review, J Cerebr Blood Flow Metab; 2014; Feb 5; doi:10.1038/jcbfm.2014.18

Soliman SA, Ishrat T, Pillai A, Somanath PR, Ergul A, El-Remessy AB, Fagan SC. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after glucose deprivation: Role of VEGF-A and VEGF-B. J Pharmacol Exp Ther 2014; March 28, DOI: 10:1124/jpet.113.212613